Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

TLR2-PI3K/Akt mediated microbe-mimetic priming boosts the therapeutic paracrine function of GelMA-Encapsulated MSCs for diabetic wound regeneration

Tian F., Kong Y., Liu Q., Zhu S., Guo X., Su Y.

Animal Study on Diabetic Foot, Chronic Wound, Immune Modulation, published in Bioact Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Bioact Mater (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41362831
PMCID
PMC12681737
DOI
10.1016/j.bioactmat.2025.10.007
Citations
6

Abstract (original English)

Chronic diabetic wounds remain a major clinical challenge due to impaired angiogenesis and dysregulated immune homeostasis. While mesenchymal stem cell (MSC) therapy holds promise, poor survival and inconsistent paracrine function limit efficacy. Herein, we present a novel biohybrid strategy that synergistically combines microbe-mimetic preconditioning of MSCs with bacterial cell wall components (peptidoglycan, PGN and lipoteichoic acid, LTA) and their sustained delivery within a gelatin methacryloyl (GelMA) hydrogel (plMSC-GelMA) to overcome these limitations. We demonstrate that dual PGN/LTA priming uniquely activates MSCs via Toll-like receptor 2 (TLR2), triggering the PI3K/Akt pathway and profoundly enhancing their pro-angiogenic (e.g., VEGF) and immunomodulatory (e.g., IL-10, TGF-β) secretome, promoting endothelial cell function and M2 macrophage polarization in vitro. Encapsulation within biocompatible GelMA hydrogel ensured prolonged viability and localized release of these potent factors. In both acute and diabetic murine wound models, plMSC-GelMA significantly accelerated wound closure, surpassing unprimed MSC-GelMA or GelMA alone. This was driven by enhanced neovascularization (CD31+/α-SMA+) and a shift towards pro-healing M2 macrophages. Mechanistic studies confirmed the pivotal role of the TLR2-PI3K/Akt axis, as genetic (siRNA) or pharmacological (LY294002) inhibiti

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research